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Prevalence and cumulative incidence of
autism spectrum disorders and the patterns
of co-occurring neurodevelopmental
disorders in a total population sample of 5-
year-old children
Manabu Saito1†, Tomoya Hirota1,2†, Yui Sakamoto1, Masaki Adachi3, Michio Takahashi3, Ayako Osato-Kaneda1,
Young Shin Kim2, Bennett Leventhal2, Amy Shui2, Sumi Kato1,4 and Kazuhiko Nakamura1,3*
Abstract
Backgrounds: Whether there is a true increase in autism spectrum disorder (ASD) frequency or not remains
unclear. Additionally, the rates of co-existing neurodevelopmental disorders (NDD) in a total population sample has
not been fully examined before. Therefore, using a total population sample in Japan, we aimed to estimate the
prevalence and cumulative incidence of autism spectrum disorder (ASD) annually, to determine whether there is a
true increase in ASD prevalence by estimating the cumulative incidence of ASD annually, and to examine the rates
of co-existing neurodevelopmental disorders (NDD).
Method: In this cross-sectional sequential design study, all 5-year-old children in the catchment area underwent the
screening annually from the year 2013–2016. Screen-positive children were invited to participate in a
comprehensive assessment, including child and parent interview, behavioral observation, and cognitive and motor
function testing. All cases were reviewed by a multidisciplinary research team.
Results: Caregivers of 3954 children returned the screening, among which 559 children underwent the assessment
with 87 children receiving an ASD diagnosis. Adjusted ASD prevalence was 3.22% (95% confidence interval (CI)
2.66–3.76%). The male to female ratio of the crude prevalence was 2.2:1. The cumulative incidence of ASD up to 5
years of age for the total study years was 1.31% (95% CI 1.00–1.62%). A generalized linear model revealed no
significant linear trends in 5-year cumulative incidence over the study years. Only 11.5% of children had ASD alone;
the remaining 88.5% were found to have at least one co-existing NDD.
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Limitations: Modest sample size for a total population study.
Conclusions: Our findings demonstrate the stability of the 5-year cumulative incidence of ASD, implying no true
rise in ASD incident cases over the 4-year study period in the study catchment area. High rates of co-existing NDDs
reflect the importance of investigating broad developmental challenges in children with ASD.
Keywords: Prevalence, Cumulative incidence, Co-existing neurodevelopmental disorders, Autism spectrum disorder,
A total population study
Introduction
The US Centers for Disease Control and Prevention has
most recently reported an increase in the autism spectrum
disorder (ASD) prevalence at 1 in 59 children [1] from that
at 1 in 68 children in its previous report [2]. This trend is
corroborated by epidemiological studies conducted in
Asian countries [3, 4], consistently reporting that the ASD
prevalence is higher than that previously reported in each
country. In an epidemiological study targeting children
aged 6–10 in China, the study findings revealed that ASD
was under-detected in mainstream schools [3]. Another
study that included five geographically diverse populations
in India reported the ASD prevalence was 1.4% among
children aged 6–9 years [4]. Furthermore, using a total
population sample and rigorous case ascertainment, Kim
et al. reported the prevalence estimate of ASDs was 2.64 %
with 95% confidence interval (CI) being 1.91–3.37 in chil-
dren in South Korea [5], which was higher than that previ-
ously reported. Most recently, a study led by the Health
Resources and Service Administration using the 2016 Na-
tional Survey of Children’s Health revealed that the ASD
prevalence based on parent reports was 2.5% in the USA
[6], supporting the findings from Kim et al. ’s study.
Despite a growing number of publications reporting
the ASD prevalence, however, few studies have examined
the ASD incidence, another measure of ASD frequency.
The limited number of incidence studies is likely due to
methodological challenges in estimating incidence [7];
more specifically, the difficulties in prospectively follow-
ing up birth cohorts until the onset of ASD and in iden-
tifying the onset time of ASD, a common challenge in
neurodevelopmental disorder. Instead, cumulative inci-
dence measure can be used to overcome these chal-
lenges. For example, the cumulative incidence of
childhood autism (based on the International Classifica-
tion of Disease and Related Health Problems, 10th revi-
sion, [8]) up to 5 years of age was measured in a birth
cohort in a population-based sample in Japan. In that
study, the authors of the above-referenced study as-
sumed that the cumulative incidence of ASD plateaus by
age 5 because it is an early childhood-onset neurodeve-
lopmental disorders (NDDs) [9]. The cumulative inci-
dence is a valuable measure of the risk of the disease or
the probability of developing the disease during the
specified time period and, therefore, can be useful for
etiological research. To the authors’ knowledge, however,
no studies examined both the prevalence and the cumu-
lative incidence of ASDs in a total population sample
using rigorous case ascertainment since Diagnostic and
Statistical Manual of Mental Disorders, 5th edition
(DSM-5) was published in 2013.
The transition to DSM-5 is important in ASD. First,
former diagnoses in DSM 4th edition, text revision, in-
cluding autistic disorder, Asperger disorder, and perva-
sive developmental disorder—not otherwise specified,
based on empirical studies, are now included under a
single diagnosis: ASD. Additionally, DSM-IV, the prior
diagnostic manual, had specified that ASD is an exclu-
sion criterion for other neurodevelopmental disorders
(NDDs), including attention deficit hyperactivity disorder
(ADHD) and developmental coordination disorder
(DCD). This rendered challenges not only for clinical
care of individuals with ASD but also for research on
phenotype and etiology among various NDDs.
The Hirosaki Five-year-old Children Developmental
Health Check-up (HFC) study was established in 2013,
using a total population sample of 5-year-old children res-
iding in Hirosaki City in Japan. The rationale for the study
arose from concerns about the limited data or follow-up
for children who screened positive for NDDs at 18-
month- or 36-month-old checkups (see Supplemental
Data for more information on these checkups in Japan),
despite a high level of participation in these assessments
(18months = 94.9%; 36months = 92.9%) [10]. There is
also a concern about whether the screen-positive children
subsequently undergo the assessment and receive appro-
priate services. The present paper uses HFC data from the
years 2013–2016 to estimate the prevalence and the cu-
mulative incidence of ASDs and to examine the patterns
of co-occurring NDDs, including ADHD, DCD, and intel-
lectual disability (ID) in children with ASD in a total popu-
lation sample of 5-year-old children in the Hirosaki
community. With these birth cohort data from children
participating in this study, we estimated the prevalence
and the 5-year cumulative incidence of ASDs for each
study year from 2013 until 2016. We hypothesized that the
5-year cumulative incidence of ASDs for each study year is
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constant, and thus increase in new ASD cases do not con-
tribute to increased prevalence estimates of ASD.
Method
Study setting and participants
The present study was conducted between 2013 and
2016 in Hirosaki, a city located in Aomori, the northern-
most prefecture in Japan. The city is about 524.20 km2
in size, with a total population of 174,171 in 71,823
households [11]. Non-Japanese residents are less than
0.5% of the total population in Hirosaki. The HFC study
targeted all 5-year-old children in Hirosaki.
Study design
Between January 2013 and December 2016, the 5-year-
old developmental check-up was held annually, produ-
cing 4 cohorts. The HFC was conducted in two stages
with the goal of detecting all children with NDDs in the
entire city.
The initial screening consisted of a set of question-
naires that the municipal health center mailed to the
caregivers and kindergarten or nursery school teachers
of all 5-year-old children in Hirosaki. The questionnaires
included demographic information (child’s sex, family
status, household income, for example) and question-
naires measuring the child’s social-emotional-behavioral
challenges, as well as caregiver’s challenges that have
been validated in Japanese populations. The second stage
of the assessment was a comprehensive evaluation of
NDDs for screen-positive children: caregivers of screen-
positive children were invited to participate in a compre-
hensive assessment conducted at the Hirosaki University
Clinic. The comprehensive assessment included child
and parent interviews along with cognitive and motor
skills assessments. The clinical data were taken together
to arrive at specific NDD diagnoses, specifically ASD,
ADHD, DCD, and ID. Figure 1 presents a flowchart of
the screening and assessment stages of the HFC study.
Initial screening stage
The initial screening questionnaires covered a wide range
of children’s social-emotional-behavioral challenges and
motor skills development. The following measures were
used (see Supplemental Data for details): Autism
Spectrum Screening Questionnaire (ASSQ), Strengths
and Difficulties Questionnaire (SDQ), ADHD-Rating
Scale-IV (ADHD-RS-IV), Developmental Coordination
Disorder Questionnaire (DCDQ), and Parenting Stress
Index (PSI) [12].
Parents completed all screeners above, and the
teachers completed the SDQ. All tools above were trans-
lated to Japanese; reliability and validity were previously
established [13–17] (Supplemental Data).
Children were considered “screen positive” if one of
the following criteria (a)–(d) was met:
a) Parent-rated ASSQ scores > 19
b) PSI scores > 75 percentile of PSI score distributions
Fig. 1 Flow chart of the Hirosaki Five-year-old Developmental Checkup and Assessment
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c) Parent-rated ASSQ scores between 9 and 19 and
parent-rated ADHD-RS total scores or at least one
of subscale scores were above-defined cutoff
d) One or more among parent-rated ASSQ, ADHD-
RS, and DCDQ scores were above the accepted clin-
ical cutoff and the teacher-rated SDQ total or one
SDQ subscale scores were above the cutoff.
Details related to cutoff scores for each screening tool
and screening criteria in the HFC study are summarized
in Supplemental Data.
Comprehensive assessment stage
All children who screened positive were invited to par-
ticipate in a comprehensive assessment conducted at the
Hirosaki University Clinic. Children who screened nega-
tive also took part in the assessment if their caregivers
requested an evaluation.
At the comprehensive assessment, developmental his-
tory and concerns were collected using items derived
from the Diagnostic Interview for Social and Communi-
cation Disorders (DISCO) [18]; the DISCO was adminis-
tered by a child psychiatrist who completed a DISCO
training course and/or graduate students who were
trained and supervised by the child psychiatrist. The
DISCO is a semi-structured interview schedule designed
to collect information on development and behavior. It
can be used to assist in identifying possible diagnostic
categories, including ASDs and other developmental dis-
orders affecting social interaction and communication.
All of parent and child interviews were videotaped for re-
view, case discussion, and determination of assessment
fidelity. Cognitive assessments were conducted by psy-
chologists using the Japanese version of the Wechsler
Intelligence Scale for Children, 4th edition (WISC-IV)
[19] only for children who did not have an ID diagnosis
before participating in the present study. For children
with a previously established ID diagnosis, the disability
certificate was examined as a reference, and research
staff confirmed that their intelligence quotient (IQ) was
below 70.
To assess children’s motor skills, the Movement As-
sessment Battery for Children, 2nd edition (MABC-2)
[20] was conducted by licensed occupational therapists
and psychologists. The MABC-2 is designed to assess
motor impairments of children in children aged 3–16
years, comprising 8 tasks: 3 measure manual dexterity, 2
measure ball skills, and 3 measure balance.
For cases in which high suspicions for ASD were raised
by the clinical and research team after reviewing scores of
the screening tools, parent and child interviews, and other
testing results, children were administered the Autism
Diagnostic Observation Schedule [21], by the research staff
with the established ADOS research reliability.
Case ascertainment
Each case was discussed in a multidisciplinary team that
included child and adolescent psychiatrists, psychologists,
a pediatrician, and occupational therapists. Best estimate
diagnosis was determined based on findings from screen-
ing tools and diagnostic assessment. DSM-5 criteria were
used for the diagnosis of ASD, ADHD, and DCD, and
both DSM-5 and the guidelines from the European
Academy of Childhood Disability [22] were used for
the diagnosis of DCD. ID diagnoses were based on an
IQ below 70.
Statistical methods
For crude prevalence estimates of ASDs for each study
year between 2013 and 2016, the denominator in the
present study was the total number of children in the
target population at the time the study was conducted
each year, and the numerator was the total number of chil-
dren who were diagnosed with ASDs each study year.
Prevalence of ASDs for the total study years between 2013
and 2016 was computed by dividing a sum of the number
of children diagnosed with ASDs each study year by a sum
of the number of all 5-year-old children in the catchment
area during the 4-year study period.
Adjusted prevalence of ASDs was computed using the
following steps: first, the ascertained sample was divided
into two groups prior to analyses:
“High-Risk Group” (HRG): these children were
identified as having disrupted development by virtue of
previous clinical contact, including evaluations and
receipt of early intervention services (e.g., speech
therapy and occupational therapy) before the
ascertainment into the HFC.
“Low-Risk Group” (LRG): these children were never the
focus of concern about developmental delays as
indicated by the lack of previous evaluations or receipt
of early intervention services.
Prevalence estimates were computed for each group and
then combined as a single estimate. Second, for missing
data on the history of service use information, values were
imputed by using the distribution of this variable from
available. Third, a latent variable for parent willingness to
come for comprehensive evaluation was developed from
patient characteristics and was tested for an association
with ASD diagnosis. As ASD diagnosis was not signifi-
cantly associated with the latent variable, we inferred that
the likelihood of an ASD diagnosis among those who were
not evaluated was not different from those who were eval-
uated and applied the ASD prevalence from the evaluated
cases to the cases that were not evaluated. The model to
predict the latent variable for parent willingness only used
those who participated in the second phase. The calculated
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number of ASD cases was then divided by the total sam-
ple, including all children who screened negative, to com-
pute the adjusted prevalence (see Supplemental Data for a
detailed analytic plan).
We compared the phenotype characteristics of individ-
uals who received ASD diagnoses between these HRG
and LRG. The chi-square test was conducted to compare
the frequency of co-existing NDDs.
For the 5-year cumulative incidence of ASD for
each study year, the number of ASD cases who were
born in the study catchment area each study year was
divided by the total number of the birth cohort in the
catchment area each study year, obtained from the
municipal database [23].
The SAS 9.4 and the SPSS (Version 25.0) were used
for statistical analyses.
Results
Between 2013 and 2016, the 5016 children born in Hiro-
saki were eligible for the study. Caregivers of 3954 chil-
dren (78.8% participation rate) completed and returned
the screening packet (ASSQ, ADHD-RS, DCDQ, SDQ,
and PSI). Preschool teachers completed the teacher-rated
SDQ for all the 3954 children. Table 1 summarized the
demographic characteristics of participating children and
their families. Detailed information about participants by
each study year is available in Supplemental Data. The
demographic data, such as sex distribution of children
and household income did not substantially differ from
national statistics or those reported in a prior large Japa-
nese epidemiological study [24, 25].
Among children who returned the screening packet,
773 children (19.5%) were screen-positive and invited to
the comprehensive assessment. Of these screen-positive
children, caregivers of 259 children either refused to con-
sent or did not bring their children for the assessment at
the University Clinic, despite having given their consent.
For screen-negative children (N = 3,181), caregivers of
45 children requested the assessment. Therefore, 559
children underwent the comprehensive in-person
assessment.
Of the 559 children, 87 children (60 boys and 27 girls)
were confirmed to have ASDs, yielding the crude ASD
prevalence for all study years of 1.73% with 95% CI of
1.37–2.10%. Sex distribution (male to female) of the
crude prevalence of ASDs was approximately 2.2:1 for
the total study years. The sex-specific crude prevalence
estimates of ASDs were 2.35% (95% CI 1.76–2.94%) in
boys and 1.09% (95% CI 0.68–1.51%) in girls. Only 21 of
these 87 children had received a diagnosis of ASD prior
to the present study.
After the adjustment for non-participants in compre-
hensive developmental assessment, the overall prevalence
of ASDs was estimated at 3.22% with 95% CI of 2.66–
3.76%. The adjusted prevalence of ASDs was 4.06% (95%
CI 3.20–4.92%) for boys and 2.22% (95% CI 1.57–2.88%)
for girls.
The cumulative incidence of ASDs up to 5 years of
age for the entire study period was 1.31% (95% CI
1.00–1.62%). The 5-year cumulative incidence for each
study year is summarized in Table 2. Although the 5-
year cumulative incidence increased from the year
2013 to the year 2014 and the year 2014 to the year
2015, further analysis, using a generalized linear
model, revealed that there were no significant linear
trends in 5-year cumulative incidence over the study
years 2013–2016 (Supplemental Data).
Of all children with ASD (N = 87), 88.5% (n = 77) of
children were found to have at least one co-occurring
NDD (i.e., one or more among ADHD, DCD, ID, and/or
borderline intellectual functioning). Of note, 20 cases
Table 1 Demographic data of children who returned screening
questionnaire between years 2013 and 2016
Total (N = 3954)
N % Mean SD
Sex
Boys 2022 51.1
Girls 1932 48.9
Age (months) 62.7 3.2
Gestational age (weeks)
< 28 26 0.7
28 < = < 37 397 10.0
37 < = < 42 3388 85.7
42 < = 143 3.6
Birth weight (g)
< 1000 12 0.3
1000 < = < 1500 16 0.4
1500 < = < 2500 349 8.8
2500 < = < 4000 3531 89.3
4000 < = 46 1.2
Family structure
living with parents 3532 89.3
living with a single parent 376 9.5
Others 46 1.2
History of developmental abnormalities 182 4.6
Familial annual income
< JPY 2 million 312 7.9
JPY 2–4 million 1242 31.4
JPY 4–7 million 1453 36.7
JPY 7–10 million 434 11.0
JPY 10 million < = 201 5.1
JPY Japanese yen
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(23%) had 3 co-occurring NDDs. Common co-occurring
conditions include ADHD 50.6% (male:female = 2.4:1),
DCD 63.2 % (male:female = 2.1:1), 36.8% ID (male:female
= 1.7:1), and 20.7% borderline intellectual functioning
(male:female = 2.6:1) (See Table 3).
Table 4 summarized comorbidity characteristics of the
children in HRG (N = 118) and LRG (N = 441) who
completed the comprehensive assessment. While the rate
of co-occurring ID was significantly higher in children
with ASD in HRG than that in children with ASD in
LRG (47.5% vs. 14.3%, respectively; p = 0.003), rates of
co-occurring ADHD and DCD were comparable for chil-
dren with ASD in both HRG and LRG (55.9% vs. 39.3%,
respectively; p = 0.15 for ADHD, 67.8% vs. 53.6%, re-
spectively; p = 0.20 for DCD).
Discussion
This sequential study design allowed us to determine
ASD prevalence estimates over 4 years (2013–2016) in a
total population sample from Japan. In each year, all 5-
year-old children in Hirosaki, Japan, were surveyed. We
Table 2 Prevalence and cumulative incidence of autism spectrum disorders for each study year and for the total study years
Year 2013 2014 2015 2016 Total
Ascertained cases male 14 13 18 15 60
female 8 7 7 5 27
total 22 20 25 20 87
N of children with ASD born in the catchment area male 8 9 14 13 44
female 5 7 6 5 23
total 13 16 20 18 67
A total N of 5-year-old children in the catchment area male 685 639 600 625 2549
female 625 622 621 599 2467
total 1310 1261 1221 1224 5016
N of 5-year-old whose caregivers returned the
screening questionnaire
male 506 496 489 531 2022
female 449 468 515 500 1932
total 954 964 1004 1031 3954
N of the birth cohort in the catchment area male 703 648 639 603 2593
female 656 610 664 589 2519
total 1359 1258 1303 1192 5112
Crude orevalence (%) (95% confidence interval: CI) male 2.04 (0.98–3.10) 2.03 (0.94–3.13) 3.00 (1.64–4.36) 2.82 (1.42–4.23) 2.35 (1.76–2.94)
female 1.28 (0.40–2.16) 1.13 (0.30–1.95) 1.13 (0.30–1.96) 0.83 (0.11–1.56) 1.09 (0.68–1.51)
total 1.68 (0.98–2.38) 1.59 (0.90–2.28) 2.05 (1.25–2.84) 1.63 (0.92–2.34) 1.73 (1.37–2.10)
Adjusted prevalence (%) (95% CI) male – – – – 4.06 (3.20–4.92)
female – – – – 2.22 (1.57–2.88)
total – – – – 3.22 (2.66–3.76)
Cumulative incidence up to 5 years of age (%) (95% CI) male 1.14 (0.35–1.92) 1.39 (0.49–2.29) 2.19 (1.06–3.33) 2.16 (1.00–3.32) 1.70 (1.20–2.19)
female 0.76 (0.10–1.43) 1.15 (0.30–1.99) 0.90 (0.18–1.62) 0.85 (0.11–1.59) 0.91 (0.54–1.28)
total 0.96 (0.44–1.47) 1.27 (0.65–1.89) 1.53 (0.87–2.20) 1.51 (0.82–2.20) 1.31 (1.00–1.62)
ASD autism spectrum disorder, Prevalence (%) N of ASD cases/the total N of target population in the catchment area × 100
Five-year cumulative incidence (%) N of ASD cases who were born in the catchment area/N of the birth cohort in the catchment area × 100
Table 3 Co-occurring patterns of neurodevelopmental disorders
(NDDs) in 87 individuals with autism spectrum disorder (ASD)
Co-occurring NDDs n %
None (i.e., ASD alone) 10 11.49
ADHD alone or ADHD and other NDDs 44 50.57
DCD alone or DCD and other NDDs 55 63.22
ID alone or ID and other NDDs 32 36.78
BIF alone or BIF and other NDDs 18 20.69
Number of co-occurring NDDs n %
0 10 11.49
1 25 28.74
2 32 36.78
3 29 22.99
*Totals may not add up because each pattern can overlap
(for example, individuals with ASD, ADHD, and DCD can be included in "ADHD
alone or ADHD and other NDDS" and "DCD alone or DCD and other NDDS").
ADHD attention deficit hyperactivity disorder, ASD autism spectrum disorder,
BIF borderline intellectual functioning (defined as IQ between 70 and 85 in this
study), DCD developmental coordination disorder, ID intellectual disability,
NDD neurodevelopmental disorder
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employed rigorous case ascertainment processes, includ-
ing initial screening and subsequent comprehensive as-
sessment that were used in the present study. Our
prevalence estimate was higher than the estimated of other
epidemiological studies in Asia [3, 5]. However, a signifi-
cant portion of our 95% CI overlaps with that of Kim
et al’s report (1.91–3.37%) [5]. Thus, observed differences
in prevalence estimates in two studies could have stemmed
from a few methodological differences (choice of assess-
ment batteries and sample size, for example).
The number of male and female children diagnosed
with ASD in the present study was 60 and 27, respect-
ively, yielding the M: F ratio of 2.2 in the total study
population after adjusting non-participants. While this
ratio is comparable to the findings in the recent NSCH
survey [6], it is lower than that reported by a recent
meta-analysis of extant studies (M;F ratio of 3.25:1 [95%
CI 2.93–3.62]) [26]. One possibility of accounting for
such discrepancy is the differences in study populations.
Compared to the studies including HRG [27, 28] alone,
these studies (i.e., present and the NSCH studies) includ-
ing both HRG and LRG tend to report lower male to
female ratios, suggesting that researchers studying indi-
viduals with ASD identified via clinical and/or educa-
tional services might have missed females with ASD.
In the present study, participating children were divided
into two groups (HRG and LRG), based on the prior use of
services/interventions. Among 87 children whose ASD
diagnosis was established in the present study, 28 children
were from LRG, comprising approximately 30% of all chil-
dren with ASD. In other words, 30% of children with ASD
had not been identified as developmentally challenged and
have not received any service/interventions until 5 years of
age. For early identification and interventions, current find-
ings emphasize the importance of continued follow-up de-
velopmental check-ups of children after 3 years of age.
The comparisons of annual 5-year cumulative ASD in-
cidence allowed us to examine whether there was a true
increase in ascertained ASD cases over the 4-year study
period. As hypothesized, no significant changes in cumu-
lative incidence of ASD have been identified in the study
catchment area. Previously, an increase in the prevalence
of ASD was considered attributable to (1) better ascer-
tainment, (2) broadened ASD diagnostic criteria, and/or
(3) a true rise in ASD incidence [29]. In the present
study, the identical methods have been used to screen
and diagnose children during the study period, minimiz-
ing the impact of methods variations. Our findings indi-
cated that cumulative incidence of ASD has been stable
during the 4-year study period. Using rigorous epidemio-
logical methods to identify cases (ASD in this study) in a
target population that includes all individuals at risk of
developing conditions (all children born and/or live in a
catchment area in this study) over significant periods (4
years in this study), our findings suggest that ASD is a
common childhood-onset NDD with stable prevalence
and incidence estimates.
Our study revealed high rates of co-occurring NDDs.
The rate of co-occurring ID is comparable to the find-
ings from extant research [30], whereas the rates of co-
occurring ADHD and DCD were higher than those re-
ported in a Swedish studies (36% vs. 51% and 37% vs.
63%, respectively) [30, 31]. These differences have come
from differences in the methods of case ascertainment
between two studies. For example, in our study, motor
function in children was assessed using a battery specif-
ically targeted to assess the movement, while it was de-
termined by the parental interview in the Swedish study.
Additionally, our study included individuals with ASD
from both HRG and LRG, whereas Swedish studies in-
cluded individuals only from HRG. High rates of co-
occurring conditions in children with ASD in our study
emphasize the necessity to evaluate co-occurring NDDs
when assessing children with ASD. Given the paucity of
available information in this area, it is particularly im-
portant and relevant with the advance of DSM-5.
Table 4 Characteristics of children who underwent diagnostic assessment (N = 559)
aHigh-risk (HR) bLow-risk (LR) HR + LR
ASD No ASD Total ASD No ASD Total
(N = 59) (N = 59) (N = 118) (N = 28) (N = 413) (N = 441) (N = 559)
N (%) N (%) N (%) N (%) N (%) N (%) N
Male 38 (64.4) 42 (71,2) 80 (67.8) 22 (78.6) 223 (54.0) 245 (55.6) 325 (58.1)
ADHD 33 (55.9) 16 (27.1) 49 (41.5) 11 (39.3) 108 (26.2) 119 (27.0) 168 (30.1)
DCD 40 (67.8) 34 (57.6) 74 (62.7) 15 (53.6) 120 (29.1) 135 (30.6) 209 (37.4)
ID 28 (47.5) 15 (25.4) 43 (36.4) 4 (14.3) 22 (5.3) 26 (5.9) 69 (12.3)
BIF 9 (15.3) 14 (23.7) 23 (19.5) 9 (32.1) 67 (16.2) 76 (17.2) 99 (17.7)
ADHD attention deficit hyperactivity disorder, ASD autism spectrum disorder, BIF borderline intellectual functioning, DCD developmental coordination disorder, ID
intellectual disability
aHigh-risk refers to children who had a history of developmental interventions prior to the study year
bLow-risk refers to children without any these interventions prior to the study year
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Limitations and strengths
The present study has several strengths: examining both
ASD prevalence and the cumulative incidence, using a
rigorous ascertainment process, use of DSM-5 criteria in
all four years, high retention (approximately 80%) of 5-
year-old children at the screening stage, sequential study
design allowing us to compare the annual 5-year cumula-
tive ASD incidence, and reporting co-occurring NDD pat-
terns in children with ASD in a total population sample,
all of which support the robustness of study findings.
Despite the strength above, findings from the present
study need to be interpreted with caution, due to the fol-
lowing limitations: first, the present study had a modest
sample size for a total population epidemiologic survey
when compared to prior studies [5, 32]. This likely affects
the precision of prevalence and incidence estimates as well
as the confidence interval of the disease proportion [30].
Second, the ADOS data, a part of gold-standard standard-
ized diagnostic assessments for ASD, were not available for
all children because some parents declined to the ADOS
testing (34 out of 87). While ASD is ultimately a clinical
diagnosis, this variation in comprehensive assessment pro-
cedures might contribute to differences in ASD prevalence
in the present study. Third, the model to predict the latent
variable for parent willingness only used those who partici-
pated in the second phase and was based on a few variables,
so it is still possible that those who were not evaluated have
a different prevalence rate. Fourth, we were unable to count
the exact number of children who moved out of Hirosaki
city prior to the 5-year-old developmental checkup in cal-
culating 5-year cumulative incidence, leading to biased inci-
dence rates toward underestimation and the cumulative
incidences toward overestimation [33]. However, the an-
nual census data reporting the number of children aged 0–
4 years from 2015 to 2019 revealed the number of these
children who moved out of the study catchment area be-
fore age 5 was relatively steady each year and considered
minimal (see Supplemental Data). Lastly, findings from the
present study may not be generalizable to other communi-
ties in which population characteristics are very different
such as great ancestral, social, cultural, and economic diver-
sity. However, our findings from this Asian population are
important given the limited number of epidemiologically
sound studies in ASD has been conducted in this region
[3–5]. Although there are still differences in ethnicity, eco-
nomics, and cultures that may impact how ASD is identi-
fied and diagnosed even within this region, the
accumulation of epidemiological findings would be
valuable.
Conclusions
With the use of the same ascertainment methods, in-
cluding screening and diagnostic tools as well as diag-
nostic criteria over the four study years, our study
indicated that there was no evidence of a true rise in
ASD prevalence and incidence over the years 2013–2016
in our catchment area. These findings lead to the conclu-
sion that ASD is a common childhood-onset NDD with
stable prevalence and incidence estimates. Replications
with larger samples and in different populations are war-
ranted in future research.
Additionally, our study demonstrated the high fre-
quency of co-existing NDDs (namely, ADHD, DCD, and
ID) in children with ASD. This finding can support the
clinical importance to provide a broad range of develop-
mental assessments rather than ASD-focused ones for
children with developmental concerns. Longitudinal
studies are required to examine how the existence of co-
occurring NDDs impacts long-term outcomes, such as
adaptive skills, psychopathology, and well-being, in indi-
viduals with ASD.
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